OTCDD

[timhyma]

Email from yesterday-
Date: Tue, 19 Feb 2002 06:33:03 -0800

From: "OTCBB News Network" <[e-mail]> / Block Address / Add to Address Book

Subject: OTCBB Newswire: DSSC: .25

To: "OTCBB News Network" <[e-mail]>

Reply-to: [e-mail]



Send to Yahoo! for review



DISEASE SCIENCES ANNOUNCES SENSATIVE DETECTION OF PRION PROTEIN IN
ABOUT 1 ML OF HUMAN URINE

Boca Raton, Florida (OTCBB Newswire), February 19, 2002 - Disease
Sciences, Inc. (DSSC: .25) announces preliminary results on the patented
urine test it has been validating for Transmissible Spongiform
Encephalopathies (“TSE”). The most common are Bovine Spongiform Encephalopathy
(“BSE”) in cattle, (commonly known as "mad-cow disease"), Scrapie in
sheep, Chronic Wasting Disease (“CWD”) in wild deer and elk and
Creutzfeldt-Jakob Disease (“CJD”) in humans. The scientists working on this
project have achieved sensitive detection of PrP in about 1mL of human
urine. The only other known studies have claimed detection of PrP in as
much as 10-50 mL of urine, but have not been able to be duplicated to
date.

The major component of the pathogen responsible for these fatal Prion
diseases is an abnormal, protease-resistant isoform of Prion protein
(PrP). Currently, definitive diagnosis of prion diseases can only be made
after the detection of the abnormal isoform of PrP in brian tissue
obtained through biopsy or autopsy. These methods are incapable for
routine diagnosis of prion disease since they are invasive, inconvenient or
unpractical.

Ongoing experiments are focused on parallel comparisons of biochemical
and structural properties of PrP between normal individuals and those
infected with CJD. Our results represent an analysis of possible
changes in molecular profile of PrP and other potential surrogate markers in
urine. We will continue the validation of the test with infected
specimens.

“We are very pleased with these breakthrough results. Such extreme
sensitivity should make the validation of the test easier,” stated Dr.
Wayne Goldstein, CEO.

The Urine diagnostic test kit was patented and developed by Bio-Tec
Global. Disease Sciences will receive royalties on sales for its part in
the validation of the test kit.

About Disease Sciences Inc. Disease Sciences, Inc. is a developmental
stage biopharmaceutical/clinical diagnostics Company. Its primary goal
will be the development of drugs through its subsidiary, HealthSpan
Sciences, Inc. HealthSpan Sciences, is developing small-molecule
pharmaceutical products that fight age-related or degenerative diseases by
attacking the underlying biochemical origins of degenerative processes. The
Company's main focus is on life-enhancing pharmaceuticals that treat
cardiovascular disease, cancer, and persistent infections. Also, the
Company plans to use a broad array of technologies to detect, identify and
quantify substances in blood or other bodily fluids and tissues. Its
goal will be a Transmissible Spongiform Encephalopathy (“TSE”) test,
useful in the diagnosis of TSE diseases such as Bovine Spongiform
Encephalopathy (“BSE”) in cattle, (commonly known as "mad-cow disease"),
Scrapie in sheep, Chronic Wasting Disease (“CWD”) in wild deer and elk and
Creutzfeldt-Jakob Disease (“CJD”) in humans. Test results are to be used
in the diagnosis, detection, evaluation, monitoring and potential
treatment of diseases and other medical conditions. The Company plans to
derive its revenues from patent sub-licensing fees, drug development,
royalties from pharmaceutical sales, appropriate milestone payments and
research and development contracts. The Company, maintains a website at
www.diseasesciences.com.


Investor Relations
[phone]
[e-mail]

The foregoing press release contains forward-looking statements that
can be identified by such terminology such as “expects”, ”potential”,
”will”, ”suggests”, ”may”, or similar expression. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results to be materially different from
any future results, performance or achievements expressed or implied by
such statements. In particular, management's expectations regarding
future research development results could be affected by, among other
things, uncertainties relating to clinical trials and product development;
availability of future financing; unexpected regulatory delays or
government regulation generally; the Company's ability to obtain or maintain
patent and other proprietary intellectual property protection; and
competition in general. Forward-looking statements speak only as to the
date they are made. The Company does not undertake to update
forward-looking statements to reflect circumstances or events that occur after the
date of the forward-looking statements are made.


Disclaimer:

International Broadcasting Corporation ("IBC") is an independent
electronic publication providing information on selected public companies.
IBC is not a registered investment advisor or a broker dealer. IBC has
been advised that the investments in companies discussed are considered
to be high risk, and use of the information provided is at the
investor's sole risk.

IBC has also been advised that the purchase of such high risk
securities may result in the loss of some or all of the investment. The
information provided by the companies reported on may include information
provided by outside sources, such as research reports, public filings or
computer databases and information provided to IBC by management of the
companies reported on. All information is obtained from sources believed
to be reliable, including company press releases, SEC Filings and other
sources, and IBC makes no representations, warranties or guarantees as
to the accuracy or completeness of the information or the disclosure by
the companies reported on. Investors should not rely solely on the
information presented. Rather, investors should use the information
regarding companies as a starting point for doing additional independent
research on the companies in order to allow the investor to form his or her
own opinion regarding investing in the companies that are reported on.

Factual statements made by the companies reported on are made as of the
date stated and are subject to change without notice. The receipt of
this information shall not create, under any circumstances, any
implication that there has been no change in the affairs of the company reported
on since the date of review. Investing in micro-cap securities is
highly speculative and carries an extremely high degree of risk. It is
possible that an investors entire investment may be lost or impaired due to
the speculative nature of the companies reported on. IBC makes no
recommendation that the securities of the companies reported on should be
purchased, sold or held by individuals or entities that learn of the
companies through IBC. Investing in micro-cap securities is highly
speculative and carries an extremely high degree of risk. It is possible that
an investor's investment may be lost or impaired due to the speculative
nature of the companies reported on. None of the securities discussed
should be construed as an offer to sell securities.

The Corporate Reporter section is a special advertising section that
features information that is not a part of the regular news content. The
Corporate Snapshot is an audio feature that appears as a part of a
Corporate Reporter advertising campaign. The Corporate Snapshot audio
feature may appear anywhere on our website, including the Radio Broadcasts
section or even the front page. Information presented in both of these
sections is provided by the advertisers, not our reporters. Disease
Sciences, Inc. (DSSC) has compensated IBC $2,000 in cash for a two-week
advertising campaign in the Corporate Reporter section starting January 7,
2002. IBC also purchased 5,000 shares (cost $5,000) of DSSC in a
private offering in July of 2001. It is possible that our advertising clients
could appear on the regular OTCBB News Network feeds as well as other
web areas like the "OTCBB Directory" or other areas under development.
Our policy for advertisers that may appear in our news is that we will
make every attempt to apply exactly the same independent and unbiased
journalistic standards to these companies as we do to all OTCBB
companies. The same disclaimer information contained above that applies to all
companies that appear in our news also applies to advertising clients